Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis

Hanfang Jiang,Quchang Ouyang,Yongmei Yin,Zhongshen Tong,Kunwei Shen,Zhongyu Yuan,Cuizhi Geng,Yaxin Liu,Guohong Song,Ran Ran,Wei Li,Qing Qu,Meiyu Wang,Luping Meng,Youzhi Tong,Huiping Li

European Journal of Cancer（2022）

引用 5|浏览20

暂无评分

摘要

•Proxalutamide showed promising activity in heavily pretreated AR+ mBC patients.•Proxalutamide showed an acceptable safety profile in heavily pretreated AR+ mBC.•Recommended phase II dose of proxalutamide was defined as 200 mg once daily.•AR expression, cell-free DNA yield, CNV might be associated with response.•Patients with PIK3CA pathogenic mutation showed longer progression-free survival.

查看译文

关键词

Proxalutamide,Metastatic breast cancer,Androgen receptor,Androgen receptor antagonist,Phase Ib study,Efficacy,Safety,Biomarker

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要